Interaction of HPV E6 oncoproteins with specific proteasomal subunits

Virology

Volumn 446, Issue 1-2, 2013, Pages 389-396

  Tomaić, Vjekoslav ^a   Ganti, Ketaki ^a   Pim, David ^a   Bauer, Christina ^b   Blattner, Christine ^b   Banks, Lawrence ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

E6; E6AP; Human Papillomaviruses; Proteasome; S5a

Indexed keywords

E6AP UBIQUITIN LIGASE; PROTEASOME; PROTEIN E6; S5A PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; UBIQUITINATION;

E6; E6AP; HUMAN PAPILLOMAVIRUSES; PROTEASOME; S5A;

CELL LINE; HOST-PATHOGEN INTERACTIONS; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN INTERACTION MAPPING; UBIQUITINATION;

EID: 84884583981     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.08.016     Document Type: Article

References (37)

1. Androphy E., Hubbert N., Schiller J., Lowy D. Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cells. EMBO J. 1987, 6:989-992.
2. Banks L., Spence P., Androphy E., Hubbert N., Matlashewski G., Murray A., Crawford L. Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas. J. Gen. Virol. 1987, 68:1351-1359.
3. Banks L., Pim D., Thomas M. Viruses and the 26S proteasome: hacking into destruction. Trends Biochem. Soc. 2003, 28:452-459.
4. Barbosa M., Schlegel R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 1989, 4:1529-1532.
5. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Benbrahim-Tallaa L., Guha N., Freeman C., Galichet L., Cogliano V. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009, 10:321-322. WHO International Agency for Research on Cancer Monograph Working Group.
6. Butz K., Ristriani T., Hengstermann A., Denk C., Scheffner M., Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003, 22:5938-5945.
7. Doorbar J., Quint W., Banks L., Bravo I., Stoler M., Broker T., Stanley M. The biology and life-cycle of human papillomaviruses. Vaccine 2012, 305:F55-F70.
8. Dyson N., Howley P., Munger K., Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243:934-937.
9. Elangovan M., Shin D., Yoo Y. The ubiquitin-interacting motifs of S5a as a unique upstream inhibitor of the 26S proteasome. Biochem. Biophys. Res. Commun. 2009, 388:723-726.
10. Funk J., Waga S., Harry J., Espling E., Stillman B., Galloway D. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 1997, 11:2090-2100.
11. Gardiol D., Kuhne C., Glaunsinger B., Lee S., Javier R., Banks L. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 1999, 18:5487-5496.
12. Gonzalez S., Stremlau M., He X., Basile J., Munger K. Degradation of the retinoblastioma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J. Virol. 2001, 75:7583-7591.
13. Hawley-Nelson P., Vousden K., Hubbert N., Lowy D., Schiller J. HPV-16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989, 8:3905-3910.
14. Huh K., Zhou X., Hayakawa H., Cho J., Libermann T., Harper J., Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 2007, 81:9737-9747.
15. Isasa M., Katz E., Kim W., Yugo V., Gonzalez S., Kirkpatrick D., Thomson T., Finley D., Gygi S., Crosas B. Monoubiquitination of RPN10 regulates substrate recruitment to the proteasome. Mol. Cell 2010, 38:733-745.
16. Jin Y., Zeng S.X., Sun X.X., Lee H., Blattner C., Xiao Z., Lu H. MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2. Mol. Cell. Biol., Feb. 2008, 28(4):1218-1229.
17. Kessis T., Slebos R., Nelson W., Kastan M., Plunkett B., Han S., Lorincz A., Hedrick L., Cho K. Human papillomavirus 16 E6 expression disrupts the p53 mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA 1993, 90:3988-3992.
18. Kish-Tier E., Hill C. Structural biology of the proteasome. Annu. Rev. Biophys 2013, (In press).
19. Martinez-Noel G., Galligan J., Sowa M., Arndt V., Overton T., Harper J., Howley P. Identification and proteomic analysis of distinct UBE3A/E6AP protein complexes. Mol. Cell. Biol. 2012, 32:3095-3106.
20. Matlashewski G., Schneider J., Banks L., Jones N., Murray A., Crawford L. Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J. 1987, 6(6):1741-1746.
21. Nakagawa S., Huibregtse J. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol. Cell. Biol. 2000, 20:8244-8253.
22. Pim D., Storey A., Thomas M., Massimi P., Banks L. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 1994, 9(7):1869-1876.
23. * protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 1997, (Pim D, Massimi P, Banks L).
24. Riley R., Duensing S., Brake T., Munger K., Lambert P., Arbeit J. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 2003, 63:4862-4871.
25. Rozenblatt-Rosen O., Deo R., Padi M., Adelmant G., Calderwood M., Rolland T., Grace M., Dricot A., Askenazi M., Tavares M., Pevzner S., Abderazzaq F., Byrdsong D., Carvunis A., Chen A., Cheng J., Correll M., Duarte M., Fan C., Feltkamp M., Ficarro S., Franchi R., Garg B., Gulbahce N., Hao T., Holthaus A., James R., Korkhin A., Litovchick L., Mar J., Pak T., Rabello S., Rubio R., Shen Y., Singh S., Spangle J., Tasan M., Wanamaker S., Webber J., Roecklein-Canfield J., Johannsen E., Barabasi A., Beroukhim R., Kieff E., Cusick M., Hill D., Munger K., Marto J., Quackenbush J., Roth J., DeCaprio J., Vidal M Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature 2012, 487:491-495.
26. Scheffner M., Werness B., Huibregtse J., Levine A., Howley P. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
27. Scheffner M., Huibregtse J., Vierstra R., Howley P. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75:495-505.
28. Smotkin D., Wettstein F. Transcription of human papillomavirus type 16 early genes in cervical cancer and cancer-derived cell line, and identification of the E7 protein. Proc. Natl. Acad. Sci. USA 1986, 83:4680-4684.
29. Thomas M., Matlashewski G., Pim D., Banks L. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene 1996, 13(2):265-273.
30. Thomas M., Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998, 17:2943-2954.
31. Thomas M., Banks L. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J. Gen. Virol. 1999, 80(Pt 6):1513-1517.
32. Thomas M., Glaunsinger B., Pim D., Javier R., Banks L. HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene 2001, 20(39):5431-5439.
33. Tomaić V., Pim D., Banks L. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. Virology 2009, 393(1):7-10.
34. Tomaić V., Pim D., Thomas M., Massimi P., Myers M., Banks L. Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD. J. Virol. 2011, 85:3120-3127.
35. Uchiki T., Kim H., Zhai B., Gygi S., Johnston J., O'Bryan J., Goldberg A. The ubiquitin-interacting motif protein, S5a, is ubiquitinated by all types of ubiquitin ligases by a mechanism different from typical substrate recognition. J. Biol. Chem. 2009, 284:12622-12632.
36. Wang Q., Young P., Walters K. Structure of S5a bound to monoubiquitin provides a model for polyubiquitin recognition. J. Mol. Biol. 2005, 348:727-739.
37. Yoshinouchi M., Yamada T., Kizaki M., Fen J., Koseki T., Ikeda Y., Nishihara T., Yamato K. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol. Ther. 2003, 8:762-768.